KR20240034222A - 인터류킨-23 수용체의 펩티드 억제제 - Google Patents

인터류킨-23 수용체의 펩티드 억제제 Download PDF

Info

Publication number
KR20240034222A
KR20240034222A KR1020247004772A KR20247004772A KR20240034222A KR 20240034222 A KR20240034222 A KR 20240034222A KR 1020247004772 A KR1020247004772 A KR 1020247004772A KR 20247004772 A KR20247004772 A KR 20247004772A KR 20240034222 A KR20240034222 A KR 20240034222A
Authority
KR
South Korea
Prior art keywords
inhibitor
interleukin
receptor
disease
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247004772A
Other languages
English (en)
Korean (ko)
Inventor
청자오 썬
산토시 니람카빌
레이먼드 제이. 패치
스테파니 에이. 바로스
샌딥 소마니
찰스 헨드릭
징 장
엘리자베타 비안치
로베르토 코스탄테
라파엘레 인제니토
다닐라 브랑카
아쇼크 반다리
브라이언 프래드릭
제임스 다니엘
트란 트렁 트란
Original Assignee
얀센 바이오테크 인코포레이티드
프로타고니스트 테라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 바이오테크 인코포레이티드, 프로타고니스트 테라퓨틱스, 인코포레이티드 filed Critical 얀센 바이오테크 인코포레이티드
Publication of KR20240034222A publication Critical patent/KR20240034222A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)
KR1020247004772A 2021-07-14 2022-07-14 인터류킨-23 수용체의 펩티드 억제제 Pending KR20240034222A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163221806P 2021-07-14 2021-07-14
US63/221,806 2021-07-14
PCT/US2022/037221 WO2023288028A2 (en) 2021-07-14 2022-07-14 Peptide inhibitors of interleukin-23 receptor

Publications (1)

Publication Number Publication Date
KR20240034222A true KR20240034222A (ko) 2024-03-13

Family

ID=84920532

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247004772A Pending KR20240034222A (ko) 2021-07-14 2022-07-14 인터류킨-23 수용체의 펩티드 억제제

Country Status (11)

Country Link
US (1) US20240409598A1 (https=)
EP (1) EP4370531A4 (https=)
JP (1) JP2024525780A (https=)
KR (1) KR20240034222A (https=)
CN (1) CN117999274A (https=)
AU (1) AU2022310354A1 (https=)
CA (1) CA3226539A1 (https=)
MX (1) MX2024000762A (https=)
TW (1) TW202332683A (https=)
UY (1) UY39856A (https=)
WO (1) WO2023288028A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
HRP20211448T1 (hr) 2014-05-16 2021-12-24 Protagonist Therapeutics, Inc. Alfa4beta7 integrin tioeter peptidni antagonisti
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
AU2021209086A1 (en) 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP7397239B2 (ja) 2020-11-20 2023-12-12 ヤンセン ファーマシューティカ エヌ．ベー． インターロイキン－２３受容体のペプチド阻害剤の組成物
EP4370146A4 (en) 2021-07-14 2025-05-21 Janssen Biotech, Inc. Lipidated peptide inhibitors of the interleukin-23 receptor
EP4652180A2 (en) * 2023-01-16 2025-11-26 Janssen Pharmaceutica NV Peptide inhibitors of interleukin-23 receptor
US20240279281A1 (en) * 2023-01-16 2024-08-22 Janssen Pharmaceutica Nv Peptide Inhibitors of Interleukin-23 Receptor
WO2024155553A1 (en) * 2023-01-16 2024-07-25 Janssen Pharmaceutica Nv Lipidated peptide inhibitors of interleukin-23 receptor
IL322423A (en) * 2023-01-31 2025-09-01 Janssen Pharmaceutica Nv Methods for preparing crystalline peptide inhibitors of the interleukin-23 receptor
CN120826233A (zh) * 2023-03-03 2025-10-21 詹森药业有限公司 用于治疗银屑病的白介素-23受体拮抗剂肽
EP4471048A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
EP4471049A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
CN121909205A (zh) 2023-09-08 2026-04-21 赛诺菲 作为选择性il-23受体抑制剂的新型肽
CN121794283A (zh) 2023-09-08 2026-04-03 赛诺菲 作为选择性il-23受体抑制剂的新型肽
WO2026013260A1 (en) 2024-07-12 2026-01-15 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2026026816A1 (zh) * 2024-07-30 2026-02-05 西藏海思科制药有限公司 白介素-23受体的肽抑制剂及其用途
WO2026041110A1 (zh) * 2024-08-22 2026-02-26 上海瀚辰星泰医药科技有限公司 一种多肽化合物及其应用
WO2026046292A1 (zh) * 2024-08-28 2026-03-05 西藏海思科制药有限公司 白介素-23受体的肽抑制剂的药物组合物及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9605027B2 (en) * 2011-06-14 2017-03-28 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
CN107206254B (zh) * 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
US10787490B2 (en) * 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MX384213B (es) * 2015-07-15 2025-03-14 Protagonist Therapeutics Inc Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias.
WO2018136646A1 (en) * 2017-01-18 2018-07-26 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2020014646A1 (en) * 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP7534382B2 (ja) * 2019-07-10 2024-08-14 プロタゴニスト セラピューティクス， インコーポレイテッド インターロイキン－２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
WO2021007433A1 (en) * 2019-07-10 2021-01-14 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3167751A1 (en) * 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Also Published As

Publication number Publication date
AU2022310354A1 (en) 2024-02-29
EP4370531A2 (en) 2024-05-22
JP2024525780A (ja) 2024-07-12
UY39856A (es) 2023-02-28
EP4370531A4 (en) 2025-09-03
WO2023288028A2 (en) 2023-01-19
TW202332683A (zh) 2023-08-16
CN117999274A (zh) 2024-05-07
MX2024000762A (es) 2024-04-18
US20240409598A1 (en) 2024-12-12
CA3226539A1 (en) 2023-01-19
WO2023288028A3 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
KR20240034222A (ko) 인터류킨-23 수용체의 펩티드 억제제
KR20240034224A (ko) 인터류킨-23 수용체의 지질화된 펩티드 억제제
KR20240034223A (ko) 인터류킨-23 수용체의 바이사이클릭 펩티드 억제제
JP7819087B2 (ja) インターロイキン－２３受容体のペプチド阻害剤および炎症性疾患を治療するためのそれらの使用
JP7441955B2 (ja) インターロイキン２３受容体のペプチド阻害剤および炎症性疾患を治療するためのその使用
JP7670605B2 (ja) インターロイキン－２３受容体のペプチド阻害剤および炎症性疾患を治療するためのその使用
JP2023511551A (ja) インターロイキン２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
JP2022540154A (ja) インターロイキン－２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
CA2997131A1 (en) Long-acting adrenomedullin derivative
CN120019064A (zh) Il-23的环肽抑制剂
HK40111925A (zh) 白介素-23受体的脂化肽抑制剂
JP2026503450A (ja) インターロイキン－２３受容体のペプチド阻害剤
HK40083331A (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240208

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application